The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2529
Abstract: Neutropenia is a dose‐related treatment‐limiting and costly adverse event of pemetrexed. We postulate that individualized dosing reduces the incidence of neutropenia. The aims of this study were (i) to investigate the costs of pemetrexed‐related neutropenia… read more here.
Keywords: neutropenia incidence; pharmacoeconomic benefits; dosing pemetrexed; incidence ... See more keywords